Spero Therapeutics (SPRO) EBITDA Margin (2017 - 2025)
Spero Therapeutics (SPRO) reported EBITDA Margin of 76.05% for Q4 2025, up 220.46 percentage points from -144.41% a year earlier and up 221.51 percentage points from the prior quarter.
Powered by 
Analysis
Spero Therapeutics (SPRO) EBITDA Margin (2017 - 2025) Analysis & Trends
For FY2025, Spero Therapeutics posted EBITDA Margin of 9.45%, up 162.36 percentage points from FY2024.
- EBITDA Margin has a five-year change of +848.82 percentage points (FY2020 to FY2025).
- By year, EBITDA Margin came in at -152.90% in FY2024 (-173.96 pp), 21.05% in FY2023 (+98.29 pp), -77.24% in FY2022 (+401.10 pp) and -478.34% in FY2021 (+361.03 pp).
- The Q4 2025 figure ranks as the highest quarterly EBITDA Margin in data going back to Q1 2017.
- Year over year, EBITDA Margin gained in three of the last six quarters, with an average year-over-year change of +113.99 percentage points.
- The high point for year-over-year EBITDA Margin in five years was Q1 2021 (a gain of 1066.90 percentage points); the low point was Q1 2022 (a drop of 1187.23 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,172.71 Bn | 1,141.30 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 643.11 Bn | 561.64 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 502.25 Bn | 475.37 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 375.34 Bn | 329.72 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 302.74 Bn | 266.73 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 268.89 Bn | 242.58 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 242.17 Bn | 197.57 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 193.67 Bn | 167.87 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 172.45 Bn | 119.10 Bn | 10.94 Bn | 39.16% |
| 10 | Spero Therapeutics | 66.95 Mn | -128.83 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 76.05% |
| Sep 30, 2025 | -145.46% |
| Dec 31, 2024 | -144.41% |
| Sep 30, 2024 | -138.04% |
| Jun 30, 2024 | -186.91% |
| Mar 31, 2024 | -150.88% |
| Dec 31, 2023 | 68.78% |
| Sep 30, 2023 | -7.17% |
| Jun 30, 2023 | -470.62% |
| Mar 31, 2023 | -682.17% |
| Dec 31, 2022 | 54.92% |
| Sep 30, 2022 | -577.12% |
| Jun 30, 2022 | -1,293.83% |
| Mar 31, 2022 | -1,450.85% |
| Dec 31, 2021 | -995.30% |
| Sep 30, 2021 | -730.29% |
| Jun 30, 2021 | -357.30% |
| Mar 31, 2021 | -263.62% |
| Dec 31, 2020 | -973.57% |
| Sep 30, 2020 | -471.31% |
API Access
Spero Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SPRO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "SPRO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SPRO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();